Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 3479.

https://doi.org/10.1182/blood-2023-182430

Published: 2023

Journal Articles

Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

Jacob D. Soumerai, Catherine S. Diefenbach, Felipe Samaniego, Abhijeet Kumar, Michaela L. Tsai, Adam S. Asch, Deepa Jagadeesh, Vaishalee P. Kenkre, Izidore S. Lossos, Huda Salman, Farrukh T. Awan, Lu Miao, Richard G. Ghalie, Andrew D. Zelenetz

Blood (2022) 140 (Supplement 1): 189–191.

https://doi.org/10.1182/blood-2022-157563

Published: 2022

Journal Articles

Novel Home-Based Transfusion Model of Palliative Care in Malignant Hematology

Blood (2022) 140 (Supplement 1): 11024–11025.

https://doi.org/10.1182/blood-2022-162527

Published: 2022

Journal Articles

Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Joseph Maakaron, Adam S. Asch, Leslie L. Popplewell, Graham P. Collins, Ian W. Flinn, Nilanjan Ghosh, Colin Keane, Matthew Ku, Amitkumar Mehta, Mark Roschewski, Carol O'Hear, Xuehan Ren, Bertha Villa, Indu Lal, Sonali M. Smith, Ranjana H. Advani

Blood (2022) 140 (Supplement 1): 3728–3730.

https://doi.org/10.1182/blood-2022-167772

Published: 2022

Journal Articles

Prevalence of neuropsychiatric symptoms and stroke in patients with hereditary thrombotic thrombocytopenic purpura

Azra Borogovac, Erika Tarasco, Johanna A. Kremer Hovinga, Kenneth D. Friedman, Adam S. Asch, Sara K. Vesely, Calin I. Prodan, Deirdra R. Terrell, James N. George

Blood (2022) 140 (7): 785–789.

https://doi.org/10.1182/blood.2022016044

Published: 2022

Includes: Supplemental data

Journal Articles

Successful Development of an Outpatient Chimeric Antigen Receptor (CAR) T Cell Therapy Program

Azra Borogovac, Amany R. Keruakous, Michelle Bycko, Jennifer Holter Chakrabarty, Sami Ibrahimi, Mohamad O. Khawandanah, George B. Selby, Carrie Yuen, Sarah A. Schmidt, Taha Al-Juhaishi, Matthew Wieduwilt, Adam S. Asch

Blood (2021) 138 (Supplement 1): 4821.

https://doi.org/10.1182/blood-2021-153457

Published: 2021

Journal Articles

Fellow As Clinical Teacher, Benign Hematology Curriculum Improves Learning and Reaction to Academic Medicine

Amany R. Keruakous, Sanober Nusrat, Tariq Khreis, Sufana Shikdar, Leslie Renee Ellis, Adam S. Asch

Blood (2021) 138 (Supplement 1): 4946.

https://doi.org/10.1182/blood-2021-144987

Published: 2021

Journal Articles

Factors Affecting Natural Killer Cell Recovery after Autologous Stem Cell Transplantation in Multiple Myeloma

Amany R. Keruakous, Raid Aljumaily, Daniel Zhao, Adam S. Asch, Carrie Yuen

Blood (2021) 138 (Supplement 1): 4895.

https://doi.org/10.1182/blood-2021-148579

Published: 2021

Journal Articles

Prevalence of Stroke and Cognitive Impairment in Patients with Hereditary Thrombotic Thrombocytopenic Purpura

Azra Borogovac, Erika Tarasco, Johanna A. Kremer Hovinga Strebel, Kenneth D. Friedman, Adam S. Asch, Sara K. Vesely, Calin I. Prodan, James N. George

Blood (2021) 138 (Supplement 1): 1008.

https://doi.org/10.1182/blood-2021-148714

Published: 2021

Journal Articles

Hybrid Cross-Discipline, Interactive Curriculum to Nurture the Training Experience for Hematology-Oncology Trainees

Amany R. Keruakous, Teresa A. Scordino, James N. George, Leslie Renee Ellis, Myles Nickolich, Adam S. Asch

Blood (2021) 138 (Supplement 1): 2981.

https://doi.org/10.1182/blood-2021-144988

Published: 2021

Journal Articles

A Phase 1, Open-Label Study of MGD013, a Bispecific DART ® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jie Wang, MD, Adam S. Asch, MD, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA, Andrew Weickhardt, MBBS(Hons) FRACP DMedSc, Monika Tomaszewska-Kiecana, Monika Dlugosz-Danecka, MD PhD, Halyna Pylypenko, MD, Shakeela Bahadur, MD, Susanna Ulahannan, MD MMed, Janine Koucheki, Jichao Sun, PhD, Hua Li, Francine Chen, MD, Xiaoyu Zhang, John Muth, MS, Patrick Kaminker, PhD, Paul Moore, PhD, Bradley James Sumrow, MD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-139868

Published: 2020

Journal Articles

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

David A Sallman, MD, Adam S. Asch, MD, Monzr M. Al Malki, MD, Daniel J. Lee, MD, William B. Donnellan, MD, Guido Marcucci, MD, Suman Kambhampati, MD, Naval G. Daver, MD, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Joanna Van Elk, Ming Lin, PhD, Jens-Peter Volkmer, MD, Chris H Takimoto, MD PhD, Mark Chao, MD PhD, Paresh Vyas, MD PhD

Blood (2019) 134 (Supplement_1): 569.

https://doi.org/10.1182/blood-2019-126271

Published: 2019

Journal Articles

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

Blood (2019) 134 (Supplement_1): 3919.

https://doi.org/10.1182/blood-2019-130635

Published: 2019

Journal Articles

Key Barriers to Clinical Trial Enrolment: A Survey of Clinical Trial Staff at an NCI Designated Cancer Center

Amany R. Keruakous, MD, Adam S. Asch, MD

Blood (2019) 134 (Supplement_1): 5864.

https://doi.org/10.1182/blood-2019-126257

Published: 2019

Journal Articles

A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy

William B. Donnellan, MD, Ehab L. Atallah, MD, Adam S. Asch, MD, Manish R Patel, MD, Julie Charlton, Alexander MacDonald, Elena Young, Elizabeth Sainsbury, Donald Strickland, MD, Suzanne Jones, PharmD, Philip Overend, Carrie A. Adelman, Jon Travers, PhD, Simon Smith, PhD, J. Elizabeth Pease, PhD, Wolfram Brugger, MD PhD

Blood (2018) 132 (Supplement 1): 4064.

https://doi.org/10.1182/blood-2018-99-118465

Published: 2018

Journal Articles

Thrombocytopenia Is a Biomarker for Response in Patients Treated with Anti PD-1/Pdl-1 Therapy

Hussein Assi, MD, Sami Ibrahimi, MD, Michael Machiorlatti, Sara K. Vesely, PhD MPH, Adam S. Asch, MD

Blood (2018) 132 (Supplement 1): 1138.

https://doi.org/10.1182/blood-2018-99-117764

Published: 2018

Journal Articles

Role of Somatic Mutations and Clonal Thrombopoiesis in Immune Thrombocytopenia

Sami Ibrahimi, MD, James George, MD, Patrick M Gaffney, MD, Sara K. Vesely, PhD MPH, Adam S. Asch, MD

Blood (2018) 132 (Supplement 1): 130.

https://doi.org/10.1182/blood-2018-99-111413

Published: 2018

Journal Articles

Preliminary Safety and Efficacy Results with an Intermittent Schedule of the PI3kδ Inhibitor ME-401 Alone or in Combination with Rituximab for B-Cell Malignancies

Andrew D. Zelenetz, MD PhD, Jacob D. Soumerai, MD, Deepa Jagadeesh, MD MPH, Nishitha Reddy, MD, Anastasios Stathis, MD, Adam S. Asch, MD, Huda S. Salman, MD, Vaishalee P. Kenkre, MD, Haresh Jhangiani, MD MBA, Alexia Iasonos, PhD, Patel Krish, MD, Richard G Ghalie, MD MBA, John M. Pagel, MD PhD

Blood (2018) 132 (Supplement 1): 2893.

https://doi.org/10.1182/blood-2018-99-115670

Published: 2018

Journal Articles

Prognostic Significance of Weight Loss and BMI during Induction Chemotherapy of Newly Diagnosed Acute Myeloid Leukemia (AML) Patients

Zachary Smith, MD, Gabriel Vidal, MD, Michael Machiorlatti, MS, Sara K. Vesely, PhD, Summer Frank, MPH, Adam S. Asch, MD, Jennifer L Holter-Chakrabarty, MD, Mohamad Khawandanah, MD, Mohamad Cherry, MD

Blood (2015) 126 (23): 5625.

https://doi.org/10.1182/blood.V126.23.5625.5625

Published: 2015

Journal Articles

Phase II Trial Daily Pulse Interleukin-2 Therapy with Famotidine during Marrow and Lymphocyte Recovery in Acute Myeloid Leukemia: LJCC 0605

Reed Friend, MD, Ridas Juskevicius, MD, Lauren Salmon, DO, Hemant S. Murthy, MD, James Xenakis, Adam S. Asch, MD, Paul Walker, MD

Blood (2015) 126 (23): 3783.

https://doi.org/10.1182/blood.V126.23.3783.3783

Published: 2015

NARROW

Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

Novel Home-Based Transfusion Model of Palliative Care in Malignant Hematology

Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Prevalence of neuropsychiatric symptoms and stroke in patients with hereditary thrombotic thrombocytopenic purpura

Successful Development of an Outpatient Chimeric Antigen Receptor (CAR) T Cell Therapy Program

Fellow As Clinical Teacher, Benign Hematology Curriculum Improves Learning and Reaction to Academic Medicine

Factors Affecting Natural Killer Cell Recovery after Autologous Stem Cell Transplantation in Multiple Myeloma

Prevalence of Stroke and Cognitive Impairment in Patients with Hereditary Thrombotic Thrombocytopenic Purpura

Hybrid Cross-Discipline, Interactive Curriculum to Nurture the Training Experience for Hematology-Oncology Trainees

A Phase 1, Open-Label Study of MGD013, a Bispecific DART ® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

Key Barriers to Clinical Trial Enrolment: A Survey of Clinical Trial Staff at an NCI Designated Cancer Center

Thrombocytopenia Is a Biomarker for Response in Patients Treated with Anti PD-1/Pdl-1 Therapy

Role of Somatic Mutations and Clonal Thrombopoiesis in Immune Thrombocytopenia

Preliminary Safety and Efficacy Results with an Intermittent Schedule of the PI3kδ Inhibitor ME-401 Alone or in Combination with Rituximab for B-Cell Malignancies

Prognostic Significance of Weight Loss and BMI during Induction Chemotherapy of Newly Diagnosed Acute Myeloid Leukemia (AML) Patients

Phase II Trial Daily Pulse Interleukin-2 Therapy with Famotidine during Marrow and Lymphocyte Recovery in Acute Myeloid Leukemia: LJCC 0605

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only